STOCK TITAN

Form 4: MAZELSKY JONATHAN JAY reports multiple insider transactions in IDXX

Filing Impact
(Very High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MAZELSKY JONATHAN JAY reported multiple insider transaction types in a Form 4 filing for IDXX. The filing lists transactions totaling 18,436 shares at a weighted average price of $629.35 per share. Following the reported transactions, holdings were 1,099 shares.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MAZELSKY JONATHAN JAY

(Last) (First) (Middle)
ONE IDEXX DRIVE

(Street)
WESTBROOK ME 04092

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/14/2026 M 958 A $0 83,422.302(1) D
Common Stock 02/14/2026 M 1,099 A $0 84,521.302 D
Common Stock 02/14/2026 F 915 D $629.35(2) 83,606.302 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (3) 02/12/2026 A 13,407 (3) (3) Common Stock 13,407 $0 13,407 D
Restricted Stock Unit (4) 02/14/2026 M 958 (4) (4) Common Stock 958 $0 0 D
Restricted Stock Unit (5) 02/14/2026 M 1,099 (5) (5) Common Stock 1,099 $0 1,099 D
Explanation of Responses:
1. Includes a total of 21 shares purchased under the Issuer's Employee Stock Purchase Plan ('ESPP') on September 30, 2025 and December 31, 2025. There are a total of 1,943.302 shares held in the ESPP which has been increased by 0.004 shares due to a rounding calculation of previously issued fractional shares.
2. Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026.
3. Grant of restricted stock units ('RSU') that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in three annual installments, beginning February 14, 2027.
4. Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments, beginning February 14, 2023.
5. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024.
Remarks:
/s/ Lily J. Lu, Attorney-in-Fact for Jonathan Jay Mazelsky 02/17/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did IDXX CEO Jonathan Mazelsky report on this Form 4?

Jonathan Mazelsky reported RSU grants, RSU-to-stock conversions, and a tax withholding share disposition. He acquired common shares from vested restricted stock units and had 915 shares withheld and delivered to satisfy tax obligations related to those equity awards.

How many restricted stock units did the IDXX CEO receive in the latest grant?

He received a grant of 13,407 restricted stock units. These RSUs will vest in three equal annual installments starting February 14, 2027 and will be deferred into an account under IDEXX’s Deferred Compensation Plan according to the disclosure footnotes.

What RSU vesting and conversions to IDEXX common stock occurred on February 14, 2026?

On February 14, 2026, 958 and 1,099 restricted stock units were exercised or converted into the same number of IDEXX common shares. Each RSU represents a contingent right to receive one share, reflecting vesting from earlier multi-year RSU awards.

Why were 915 shares of IDEXX common stock disposed of in this Form 4 filing?

The 915 shares were disposed of to pay tax liabilities tied to equity vesting. The transaction used a price of $629.35 per share, matching the stated closing price on Nasdaq for IDEXX stock on February 13, 2026, as noted in the footnotes.

What is Jonathan Mazelsky’s direct common stock ownership in IDEXX after these transactions?

After the reported transactions, he directly owned 83,606.302 IDEXX common shares. This total includes 1,943.302 shares held through the company’s Employee Stock Purchase Plan, which incorporates 21 shares purchased in late 2025 and a small rounding adjustment.

How do the new RSUs for the IDXX CEO vest compared with earlier RSU awards?

The new 13,407-unit RSU grant vests in three annual installments starting February 14, 2027. Earlier RSU awards mentioned in the footnotes vest over four annual installments beginning February 14, 2023 and February 14, 2024, highlighting differing vesting schedules across grants.
IDEXX Laboratories

NASDAQ:IDXX

IDXX Rankings

IDXX Latest News

IDXX Latest SEC Filings

IDXX Stock Data

50.70B
79.30M
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
Link
United States
WESTBROOK